William Blair Has Optimistic Outlook of TERN FY2027 Earnings

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) – Analysts at William Blair lifted their FY2027 earnings per share (EPS) estimates for Terns Pharmaceuticals in a research report issued to clients and investors on Monday, November 3rd. William Blair analyst A. Hsieh now forecasts that the company will post earnings of ($1.35) per share for the year, up from their previous forecast of ($1.41). William Blair has a “Outperform” rating on the stock. The consensus estimate for Terns Pharmaceuticals’ current full-year earnings is ($1.19) per share.

Terns Pharmaceuticals (NASDAQ:TERN) last posted its earnings results on Tuesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.02.

Other equities research analysts also recently issued research reports about the company. Jefferies Financial Group raised their price target on Terns Pharmaceuticals from $28.00 to $35.00 and gave the stock a “buy” rating in a report on Monday. Oppenheimer reissued an “outperform” rating and issued a $24.00 price target on shares of Terns Pharmaceuticals in a report on Monday. Wall Street Zen raised Terns Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, October 25th. Mizuho raised their price target on Terns Pharmaceuticals from $9.00 to $32.00 and gave the stock an “outperform” rating in a report on Tuesday. Finally, Truist Financial reissued a “buy” rating and issued a $28.00 price target (up previously from $20.00) on shares of Terns Pharmaceuticals in a report on Tuesday. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $25.38.

Terns Pharmaceuticals Price Performance

TERN opened at $18.19 on Thursday. The business’s 50-day moving average is $8.32 and its two-hundred day moving average is $5.80. Terns Pharmaceuticals has a 1 year low of $1.87 and a 1 year high of $18.75. The firm has a market capitalization of $1.59 billion, a PE ratio of -17.49 and a beta of -0.02.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of TERN. Vontobel Holding Ltd. acquired a new position in Terns Pharmaceuticals in the first quarter valued at approximately $39,000. Invesco Ltd. lifted its holdings in Terns Pharmaceuticals by 149.3% in the first quarter. Invesco Ltd. now owns 58,345 shares of the company’s stock valued at $161,000 after acquiring an additional 34,945 shares during the period. Nuveen LLC acquired a new position in Terns Pharmaceuticals in the first quarter valued at approximately $3,880,000. Wellington Management Group LLP lifted its holdings in Terns Pharmaceuticals by 44.3% in the first quarter. Wellington Management Group LLP now owns 321,163 shares of the company’s stock valued at $886,000 after acquiring an additional 98,649 shares during the period. Finally, EntryPoint Capital LLC lifted its holdings in Terns Pharmaceuticals by 21.4% in the first quarter. EntryPoint Capital LLC now owns 73,293 shares of the company’s stock valued at $202,000 after acquiring an additional 12,905 shares during the period. 98.26% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Terns Pharmaceuticals

In related news, Director Jill M. Quigley sold 24,520 shares of Terns Pharmaceuticals stock in a transaction dated Tuesday, November 4th. The stock was sold at an average price of $18.00, for a total transaction of $441,360.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 1.50% of the stock is owned by company insiders.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.